Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsLatest reported annual revenue changed -3.0% from the prior reported annual observation.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Revenue contracted
Latest reported annual revenue changed -3.0% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Operating margin compressed
Operating margin changed -18.8 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- 4 filing risk checks flagged
Flagged areas: Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Free cash flow was positive
Latest reported free cash flow was $1.9B.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Brands$9.18Bshare n/a-0.2% yoy
- Generics$5.07Bshare n/a-7.8% yoy
- Lipitor$1.55Bshare n/a+5.5% yoy
- Norvasc$710Mshare n/a+5.4% yoy
- Lyrica$487Mshare n/a-1.7% yoy
- Epi Pen Auto Injectors$470Mshare n/a+19.8% yoy
- Viagra$408Mshare n/a+3.2% yoy
- Creon$366Mshare n/a+11.5% yoy
- +9 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$3.01B59.1%-12.5% yoy
- China$2.08B40.9%+8.8% yoy
Members sum to $5.09B against $14.3B consolidated (residual $9.16B) - eliminations or corporate lines the filer did not tag on this axis.
- Developed Markets Segment$2.03B57.6%+6.7% yoy
- Greater China Segment$680M19.3%+22.4% yoy
- Emerging Markets Segment$537M15.3%+2.7% yoy
- Japan Australia And New Zealand Segment$274M7.8%-1.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 3,990 US-listed filers · 777 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $14.3B | 91stof 3,301 top third | 94thof 522 top third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | -3.0% | 22ndof 3,137 bottom third | 27thof 473 bottom third |
Gross margin gross profit ÷ revenue | 35.2% | 45thof 1,603 middle third | 55thof 221 middle third |
Operating margin operating income ÷ revenue | -18.7% | 27thof 2,819 bottom third | 52ndof 483 middle third |
Net margin net income ÷ revenue | -24.7% | 23rdof 3,263 bottom third | 46thof 518 middle third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 13.6% | 74thof 2,679 top third | 83rdof 433 top third |
Return on equity net income ÷ stockholders' equity (positive equity only) | -23.9% | 27thof 3,576 bottom third | 59thof 701 middle third |
Interest coverage operating income ÷ interest expense (interest expense > 0) | -5.7× | 26thof 819 bottom third | 50thof 155 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 1.3% | 62ndof 2,895 middle third | 73rdof 476 top third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 78 days | 21stof 2,398 bottom third | 28thof 387 bottom third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | 4.8× | 28thof 1,546 bottom third | 25thof 145 bottom third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -14.8% | 92ndof 1,333 top third | 93rdof 164 top third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | -21.0% | 93rdof 1,073 top third | 89thof 133 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 2 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | fiscal year 2023-12-31 | $2.8B 10-K 2024-02-28 | $2.9B 10-K 2026-02-26 | +3.6% | first · latest · 3 filings carry it |
| Operating cash flow NetCashProvidedByUsedInOperatingActivities | fiscal year 2022-12-31 | $2.95B 10-K 2023-02-27 | $3B 10-K 2025-02-27 | +1.6% | first · latest · 3 filings carry it |
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for VTRS yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.